Carboplatin Injection, generic of Paraplatin, launched in the U.S. market
Natco Pharma launches Carboplatin Injection, a generic of Paraplatin, in the U.S. market via its U.S. subsidiary Natco Pharma USA LLC.
By ScoutQuest · · 1 min read
- Estimated U.S. Sales
- USD 27.8 million in the 12 months ending June'26
- Product
- Carboplatin Injection, a generic of Paraplatin
- Manufacturing Collaboration
- Teyro Labs Pvt Ltd
Natco Pharma has launched Carboplatin Injection, a generic version of Paraplatin, in the U.S. market. The announcement came through a press release shared with the exchanges.
What was announced
- The launch is in the U.S. market, through the company's U.S. subsidiary, Natco Pharma USA LLC.
- The product is made in manufacturing collaboration with Teyro Labs Pvt Ltd, based in Chennai.
- The company says the launch helps address a critical shortage of the product in the U.S. market.
Market size cited
Carboplatin Injection had estimated sales of USD 27.8 million in the U.S. for the 12 months ending June'26, as per industry sales data. This is the estimated size of sales of the product in that market. It is not a statement of the revenue Natco expects from it.
What the medicine is for
Carboplatin Injection is indicated for the treatment of advanced ovarian carcinoma, including first-line combination therapy and palliative treatment of recurrent disease after prior chemotherapy. The release refers readers to the full Prescribing Information for complete indications, limitations and important safety information.
Company details given in the release
- 9 manufacturing sites and 2 R&D facilities in India
- Facilities approved by regulators such as the US FDA, Brazil ANVISA, Health Canada and WHO
- Products catering to 50+ global markets
- Describes itself as an R&D oriented oncology player in the domestic market, focusing on limited-competition molecules in the U.S.
Points to keep in mind
- A launch adds a product to the U.S. portfolio. How much it earns depends on actual offtake, pricing and competition in that market.
- The market-size figure above is industry sales data for the molecule, which shows the size of the opportunity rather than the company's share of it.
Also from Natco Pharma
Allotment of ~1.71 crore equity shares at ₹750 each under rights issue
23 Oct 2026
Rights Issue period closes today; issue of up to Rs.12,794 millions approved at Rs.750 per share
22 Oct 2026
Natco Pharma in focus after Abu Dhabi Investment Authority acquired 1.73 lakh shares
19 Oct 2026
More numbers
- Estimated U.S. sales of Carboplatin Injection, 12 months to June'26USD 27.8 million
- Period covered by the cited sales data12 months
- Manufacturing sites in India9
- R&D facilities in India2
- Global markets catered to50+
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.